Zobrazeno 1 - 10
of 154
pro vyhledávání: '"DLBCL—diffuse large B cell lymphoma"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically th
Externí odkaz:
https://doaj.org/article/e626138fcfab4fad9089359115afeea4
Autor:
Kanwal Asghar, Maryam Zafar, Eva Holland, Ali Bin Abduljabbar, Sara A. Albagoush, Noureen Asghar, Akshat Sood, Jalal M. Dufani, Joseph Thirumalaredy, Bradley DeVrieze, Abubakar Tauseef, Muhammad Husnain
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionInconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell
Externí odkaz:
https://doaj.org/article/5ca47676a1184f45ba516d15dd1a524a
Autor:
Ivan Odak, Lâle M. Bayir, Lennart Riemann, Ruth Sikora, Jessica Schneider, Yankai Xiao, Nora Möhn, Thomas Skripuletz, Gernot Beutel, Matthias Eder, Arnold Ganser, Reinhold Förster, Christian R. Schultze-Florey, Christian Koenecke
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19+ B-cell malignancies. Using a 31-color spectral
Externí odkaz:
https://doaj.org/article/5786ca34b273415fb85d64d76fb3aa83
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chung C
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 12, Pp 99-106 (2022)
Clement Chung Department of Pharmacy, Houston Methodist West Hospital, Houston, TX, USACorrespondence: Clement Chung, Houston Methodist West Hospital, 18500 Katy Freeway, Houston, TX, 77094, USA, Tel +1-832-522-1051, Email clement_t_chung@yahoo.comAb
Externí odkaz:
https://doaj.org/article/c698e438326a47bf91230abd9bf46252
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short su
Externí odkaz:
https://doaj.org/article/617f5691a8e74047b11c6b9eeaa33179
Autor:
Nikeshan Jeyakumar, Melody Smith
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Cellular therapies have transformed the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), which typically does not respond well to salvage chemotherapy. Recently, approximately 40% of r/r DLBCL patients across three differen
Externí odkaz:
https://doaj.org/article/12c905afe507433bbcb5adae9131d79a
Publikováno v:
Frontiers in Surgery, Vol 9 (2022)
In the pituitary sella, the coexistence of pituitary adenoma and primary pituitary lymphoma is exceedingly rare. Thus far, only six cases have been reported. Here, we present the seventh case of coexisting pituitary adenoma and primary pituitary lymp
Externí odkaz:
https://doaj.org/article/9afdafe1373e446ab926a1689ded9837
Autor:
Lingshuang Sheng, Di Fu, Yiwen Cao, Yujia Huo, Shuo Wang, Rong Shen, Pengpeng Xu, Shu Cheng, Li Wang, Weili Zhao
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundDiffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma and related to autoimmune diseases (AIDs). Primary B-cell receptor-mediated AIDs are associated with poor clinical outcome of DLBCL. To further determine the r
Externí odkaz:
https://doaj.org/article/efbd2121c3f145858723bb22aaa5f70d
Autor:
Willem Daneels, Michael Rosskamp, Gilles Macq, Estabraq Ismael Saadoon, Anke De Geyndt, Fritz Offner, Hélène A. Poirel
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged ≥20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013–2015). Treatments we
Externí odkaz:
https://doaj.org/article/65196fe6552349728fcf6bf86956353a